CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Islet Holdings, Inc. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Islet Holdings, Inc.
3060 W 3650 S Apt 92
Phone: (385) 222-6281p:385 222-6281 WEST VALLEY CITY, UT  84119-4340  United States Ticker: ISHIISHI
This company ceased filing statements with the SEC on 5/1/2008.
Business Summary
Islet Holdings Inc. is a biotechnology company, which is focused on cosmeceuticals. The Company is engaged in the research, development and commercialization of patented technologies in the field of transplantation in the therapy of people with conditions of insulin-dependent diabetes. The Company is developing intellectual property relating to hemp farming and extraction of cannabidiol (CBD) from hemp. Its technology constitutes methods for isolating, culturing, cryopreservation and immune-protection (microencapsulation) of islet cells. The Company's product candidates are intended for the treatment of insulin-dependent diabetes and are intended to be administered into the patient's abdominal cavity, where the transplanted islet cells will produce insulin in response to increase in blood glucose. The primary function of microencapsulation is to protect the islets from the host's immune system. The microcapsule coating is composed of layers of biocompatible materials.
(Source: ARS)

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
6/30/20029/30/2001YesYes---

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
8731 Commercial physical and biological research
0139 Field crops, except cash grains, not elsewhere classified

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board James S.Chapin 49 1/1/2001 1/1/2001
President MartiWolf 64 7/14/1999 7/14/1999
Chief Financial Officer, Director Stan R.Wylie 64 9/28/2000 12/1/1995
3 additional Officers and Directors records available in full report.

Business Names
Business Name
BIOZHEM Cosmeceuticals
ISHI
Islet Holdings Inc
Isletech, Inc.

General Information
Number of Employees: 7 (As of 9/30/2001)
Outstanding Shares: 206,200,000 (As of 7/28/2015)
Shareholders: 620
Stock Exchange: OTC
Federal Tax Id: 760118305
Email Address: info@biozhem.com


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Monday, August 28, 2023